Chul Kim @chulkimMD Twitter profile

Last Seen Profiles

@Jr3Bell

@Mpho1456239

@culebalde

@YohanesMaryono4

@Slosa182536

@NanakoQAQ

@VALA_TX

@CSFalconsFB

@nantucket1999

@marchnotia

@elenaasantoyoo

@VCerdaGar

@RayCastillo05

@davidblancopz

@cheesecakey_69

@AD4xN8ohtffhBv9

@drmalaksohaib

@sotwecom

@tala1303302

@e3tweeter

@ailedglz

@DiegoEnricoMD

@elle_vegas

@SM78383093

@SelenaFanChile

@JohyRV

@DiegoEnricoMD

@VictoriousNamo

@DerrionBarthol1

@BinorRaja

@atletikingston

@RayTrainToTrop

@borapill

@stwmaniax

@Papuaviral1

@PeachyLIly3

Chul Kim

@chulkimMD

10 months

The Tumor Board ( #LCSM theme)

10

110

579

Chul Kim

@chulkimMD

3 years

My little tumor board buddy. He accumulated more than 10 CME credits during the pandemic by attending the tumor board religiously. 😂

4

2

405

Chul Kim

@chulkimMD

10 months

Finished inpatient rounds for today. Cancer sucks. May 2024 bring more effective treatment options for patients.

16

17

269

Chul Kim

@chulkimMD

1 year

Thrilled to announce that I have been promoted to Associate Professor of Medicine! I am incredibly grateful for the unwavering support and guidance of my mentors, colleagues, and beloved family throughout my career journey.

58

5

203

Chul Kim

@chulkimMD

2 years

As an oncologist, saying "I wish I had more treatment options to offer" is never easy. But doing less can sometimes be the best way to do more.

1

9

152

Chul Kim

@chulkimMD

5 years

‘KRAS(G12C)-mutant cancer cells can rapidly bypass the effects of treatment with KRAS(G12C) inhibitors because a subset of cells escapes drug-induced quiescence by producing new KRAS(G12C) that is maintained in its active, drug-insensitive state’

4

69

134

Chul Kim

@chulkimMD

1 year

Celebrating 7 years of relentless effort, hard work, and sleepless nights encapsulated in these photos Overjoyed to see my better half, now Dr. Jihye Park, DDS, reach this milestone Her journey exemplifies resilience as a first-gen immigrant, devoted mom, & tenacious student

9

2

105

Chul Kim

@chulkimMD

3 years

Patient: "I feel like I am a different person with this pill (targeted therapy). I have never felt better. Thank you" Being an oncologist is often not easy Moments like this are so precious

0

6

94

Chul Kim

@chulkimMD

2 years

This picture brings back memories of @ASCO 2018, my first ASCO as an attending. The baby in the picture became my tumor board buddy during the pandemic 😆

1

0

85

Chul Kim

@chulkimMD

1 year

On my way to the airport to visit family in S. Korea. It has been 4 years since the last visit. Missed several family events including my brother’s wedding. Excited 😊

10

0

84

Chul Kim

@chulkimMD

4 years

This recognition from hematology/oncology fellows @LombardiCancer @MedStarGUH means a lot to me. I always aspired to be a good teacher, but never thought I would make a good one. I am deeply honored and humbled to receive the teaching award.

8

5

81

Chul Kim

@chulkimMD

1 year

Honored to present data on MET fusion positive NSCLC, a collaborative work through @carisls Precision Oncology Alliance! A thread (1/7)2297)

3

18

76

Chul Kim

@chulkimMD

1 year

At the airport en route to Singapore for #WCLC23 ! Excited about reconnecting with colleagues from around the world and making new collaborative connections.

6

1

69

Chul Kim

@chulkimMD

3 years

My first text book chapter is out! It was my honor to work with my mentor, colleague, and friend, Dr. Beppe Giaccone. #thymoma #thymic_carcinoma #thymus

5

1

66

Chul Kim

@chulkimMD

3 years

While there is much more work to be done, the field of thoracic oncology has seen tremendous advances in the past decade. I am sure that in 10 years, the list would be filled with more molecular targets and more effective/novel therapies. #LCSM

1

13

63

Chul Kim

@chulkimMD

3 years

@JessLynnMoreno More of phrases - Poor historian - Patient failed treatment - patient failed to meet trial eligibility criteria

4

5

64

Chul Kim

@chulkimMD

1 year

Life can throw a lot at you, but it’s nice when some things stay the same. I am in my old room at my parents’ place, and looking out the window. Seoul has not changed much from here, and I am thankful for that.

5

2

64

Chul Kim

@chulkimMD

2 years

Our own Dr. @StephenVLiu won the Heine H. Hansen Lectureship Award for Small Cell Lung Cancer! Very well deserved recognition. Big congratulations!! @LombardiCancer @MedStarGUH

Dr. Antonio Calles 🫁🚭

@Tony_Calles

2 years

Really happy to see @StephenVLiu Lectureship Award for Small Cell Lung Cancer. Really eager to attend on Monday (also live streamed) at Hall C1, 1:30-2:30 PM. Well deserved my friend. Congrats!👏 #WCLC22 #LCSM @IASLC

21

15

154

6

61

Chul Kim

@chulkimMD

1 year

NYC marked my first encounter with the U.S. as I undertook my clerkship at Mount Sinai for two months, being a medical student from South Korea The summer of 2006 continues to hold a prominent place in my memory Each time I visit NYC, those past memories and feelings resurface

6

0

59

Chul Kim

@chulkimMD

5 years

Logged into @IASLC website to renew my IASLC membership. Hmm, that serious looking guy looks familiar. ….. Oh it was me!! My honor to be on the IASLC homepage :) #LungCancerAwarenessMonth

8

4

59

Chul Kim

@chulkimMD

8 months

With my mentee, Dr. Vanya Aggarwal, a 2nd-year fellow at @GeorgetownHOF @LombardiCancer . Congratulations on receiving the Travel Award for #TTLC24 . It’s a well-deserved honor. I am fortunate to work with Dr. Aggarwal.

0

5

60

Chul Kim

@chulkimMD

3 years

IIT of pembro + platinum-based chemo in recurrent EGFR/ALK+ NSCLC by Dr. Gadgeel & colleagues ORR/PFS/OS in EGFR (N=26): 42.3%/8.3 mo/22.2 mo ORR/PFS/OS in ALK (N=7): 28.6%/2.9 mo/2.9 mo Ongoing KEYNOTE-789 will shed further light on the role of chemoIO in EGFR+ NSCLC #WCLC21

0

15

58

Chul Kim

@chulkimMD

2 years

Our project on the expression of Trop-2 in thymic epithelial tumors (TETs) presented @Itmig_society Trop-2 is highly expressed in thymoma (94%) and thymic carcinomas (100%) with lower expression in normal thymic tissue. Trop-2 is a potential therapeutic target in TETs!

4

14

59

Chul Kim

@chulkimMD

1 year

Fortunate to celebrate mom's birthday in Seoul. Next stop, Singapore! #WCLC23

1

3

58

Chul Kim

@chulkimMD

3 years

A phase II trial of first-line cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma (JME-001) N=18 ORR=77.8% (14 PRs out of 18) mPFS=8.02 mo mOS=20.8 mo Grade 3 or higher AEs=55.6% Small study, but encouraging results

2

16

58

Chul Kim

@chulkimMD

8 months

Excited to be attending #TTLC24 ! Can’t wait to see everyone in Santa Monica and looking forward to engaging discussions.

1

0

58

Chul Kim

@chulkimMD

4 years

Our phase I trial of lutathera/nivolumab in ES-SCLC & pulm NETs is finally published @jitcancer . 5 years of teamwork. Many thanks to all the co-authors @StephenVLiu , Deepa Subramaniam, Tisdrey Torres, @MassimoLodaMD , Giuseppe Esposito & Beppe Giaccone.

3

10

58

Chul Kim

@chulkimMD

3 years

Thank you to @ASCO for naming me an Advocacy Champion for my continued commitment to advocating for issues affecting the #oncology community. You can be an Advocacy Champion too by getting involved today: #ASCOAdvocacySummit

4

3

57

Chul Kim

@chulkimMD

5 years

Our paper on safety/efficacy of IO based therapy in pts with HIV and/or viral hepatitis out! Notable findings: 1) IO not a/w viral reactivation c/w prior reports, 2) no concerning irAEs with chemo+IO, 3) among responders, some had low CD4 (need validation in larger studies).

Stephen V Liu, MD

@StephenVLiu

5 years

#OncoAlert Safety & efficacy of IO in patients with HIV or hepatitis, published @jitcancer - adds to a growing body of evidence. Proud to be part of this @LombardiCancer effort led by @chulkimMD , @NeilSha26672667 , @subhamadhavan , Mike Atkins, Geoff Gibney

0

23

41

3

16

54

Chul Kim

@chulkimMD

2 years

Had a farewell lunch with Dr. Vincent Yeung, my mentee who will join @RutgersCancer as a thoracic oncologist Very proud of his achievements and excited about his next chapter in life and career. He will be sorely missed.

1

2

53

Chul Kim

@chulkimMD

2 years

Our case report is out #JTOCRR @JTOonline ! Here we describe a patient with KRAS G12C-mutated lung adenocarcinoma and untreated brain metastases who achieved significant clinical and radiographical response to #sotorasib .

1

12

52

Chul Kim

@chulkimMD

2 years

At fellowship graduation last night, our fearless leader, Dr. Marshall @marshalj23 received Teaching Attending Award chosen by @LombardiCancer hematology/oncology fellows! Congratulations! 🍾🎊🎉

4

5

52

Chul Kim

@chulkimMD

3 years

Our paper describing longitudinal ctDNA analysis in blood and saliva in EGFR-mutant lung adenocarcinoma is out @cancers ! Here we utilized three different ctDNA platforms (ddPCR and NGS for blood, EFIRM liquid biopsy for saliva). (Thread)

4

17

51

Chul Kim

@chulkimMD

3 years

This phase I trial means much to me First IIT I wrote as a cancer researcher Can't thank enough my colleagues. This was team work. I will remain forever grateful to the patient and their caregivers for their participation and believing in our team for care. @LombardiCancer

Stephen V Liu, MD

@StephenVLiu

3 years

Phase I study of first line osimertinib + dasatinib in patients with #EGFR NSCLC led by Dr. @chulkimMD now online @FrontOncology . Based on targeting CRIPTO via Src which may mediate EGFR TKI resistance. Small study but 90% had a response with one ongoing.

1

14

34

11

2

51

Chul Kim

@chulkimMD

3 years

That feeling when a manuscript you have been working on for two years found a home after five rejections.. #academiclife

3

0

50

Chul Kim

@chulkimMD

3 years

Happy to share a case report of ALK fusion mediating resistance to osimertinib @JTOonline . Partial response seen with osimertinib/alectinib. Understanding resistance mechanisms is important after progression on osimertinib. @StephenVLiu @Joshua_Reuss

1

10

49

Chul Kim

@chulkimMD

9 months

People with HIV are diagnosed with lung cancer 10-15 years earlier than the general population. We need to better understand the risk factors and optimize lung cancer screening for PWH. Our team, led by @randimwilliams2 , will delve into this topic! Grateful for funding from

Georgetown Cancer Prevention and Control Program

@GeorgetownCPC

9 months

Congrats to @RandiMWilliams2 , @chulkimMD , Jeanne Mandelblatt ( @GUCancerAging ), and Marta Catalfamo ( @DC_CFAR ) who have received pilot funding to modify a #LungCancer risk model to include #HIV related parameters! This project could inform future lung screening guidelines. #HIVonc

0

6

18

4

10

49

Chul Kim

@chulkimMD

2 years

MET alteration is an important resistance mechanism to EGFR-TKI therapy Great work by Dr. Molly Wilgucki on our case report "Osimertinib and capmatinib combination therapy to overcome MET Y1003N-mediated resistance in EGFR-mutant NSCLC" @JTOonline

1

13

49

Chul Kim

@chulkimMD

11 months

It truly takes a village to conduct and care for patients in clinical trials. Clinical trial team dinner hosted by our leader @StephenVLiu . Grateful to work with such supportive and dedicated colleagues @LombardiCancer !

2

3

48

Chul Kim

@chulkimMD

1 year

First selfie #ASCO2023 with the one and only @benlevylungdoc !

1

47

Chul Kim

@chulkimMD

1 year

Thrilled for my mentee, Dr. Jacob Zaemes @GeorgetownHOF receiving ASCO #YIA ! His project centers on B7-H3 ADC (MGC018) development for ES-SCLC, including EGFR+ NSCLC to SCLC transformation. Grateful for co-mentorship of @StephenVLiu and research support from @ChristianRolfo .

4

5

47

Chul Kim

@chulkimMD

4 years

STK11 and KEAP1 mutations in KEYNOTE-042. STK11 mutation a/w lower PD-L1 expression. Pembro a/w better outcomes compared with chemo, regardless of STK11 or KEAP1 mutation status. Very low ORR with chemo in STK11 mutation+ NSCLC. #AACR20 @OncoAlert

0

24

46

Chul Kim

@chulkimMD

1 year

Dr. Janne presented the awaited #FLAURA2 trial results, comparing osimertinib plus platinum-pemetrexed to osimertinib alone. The combination yielded a mPFS of 25.5 months versus 16.7 months, with a HR of 0.62. This benefit, especially evident in patients with baseline CNS

1

21

46

Chul Kim

@chulkimMD

5 years

Phase II trial of durvalumab in HIV+ pts with cancer. 14/20 had NSCLC. 4 (29%) of 14 NSCLC responded to durva (3/4 responders PD-L1 +). No G3 or 4 trAEs. CD4/CD8/viral load stable during treatment. PD-(L)1 blockade feasible and safe in HIV+ pts @JAMAOnc

Assessment of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection

This nonrandomized phase 2 study assesses the feasibility and safety of durvalumab treatment in adults with advanced solid tumors and HIV-1 infection.

jamanetwork.com

1

11

44

Chul Kim

@chulkimMD

1 year

How it started How it is going (2018) (2023) 👇 👇 So proud of Dr. Jacob Zaemes @GeorgetownHOF @LombardiCancer ! Incredibly grateful to @ConquerCancerFd for continued support.

3

1

45

Chul Kim

@chulkimMD

9 months

As an oncologist, one of the joys is seeing patients respond well to immunotherapy, which can often induce a lasting response. Increasing the reach of IO to driver-positive NSCLC (e.g. EGFR/ALK+ NSCLC), where immunotherapies tend not to work well, is an urgent and unmet need.

4

2

45

Chul Kim

@chulkimMD

2 years

Although I miss catching up with colleagues at #TTLC23 , I'm overjoyed that today my wife has been given the green light to walk again after 6 weeks of non-weight bearing due to a fracture. Thankful for the excellent care provided by the whole @MedStarGUH team ♥️

6

0

45

Chul Kim

@chulkimMD

5 years

Durvalumab plus chemo (CASPIAN) published in @lancet . OS benefit with durva in recalcitrant ES-SCLC. Still lots of Qs: predictive biomarkers, ways to make the triplet therapy better (need a 4th drug?). #LCMS @OncoAlert

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive...

First-line durvalumab plus platinum–etoposide significantly improved overall survival in patients with ES-SCLC versus a clinically relevant control group. Safety findings were consistent with the...

www.thelancet.com

3

20

44

Chul Kim

@chulkimMD

1 year

Life leads us down various pathways, and often times, it becomes challenging to spend as much time with our loved ones as we desire. However, in those moments, we come to realize that these instances may actually be among the most precious days of our lives.

2

0

44

Chul Kim

@chulkimMD

3 years

Check out our poster on genomic/immunologic characterization of LCNEC of the lung. We show that LCNEC and SCLC share molecular features, but distinct patterns of genomic alterations and transcriptome profiles were demonstrated. Grateful to all the co-investigators! @carisls

3

12

42

Chul Kim

@chulkimMD

1 year

Our very own Dr. @StephenVLiu presenting the 5-year OS data from IMpower133 and its extension, Imbrella A. 5-year OS rate for first-line platinum chemotherapy combined with atezolizumab stands at 12%. A critical benchmark for upcoming studies! #WCLC23

0

8

42

Chul Kim

@chulkimMD

1 year

Phase III trial of benmelstobart (anti-PD-L1), anlotinib & chemo for ES-SCLC. PFS & OS improved: mOS 19.3 vs 11.9 mo (HR: 0.61). Despite promising data, IMO, the exact role of adding anti-angiogenesis to chemo-IO is unanswered due to a missing chemo-IO w/o anlotinib arm. #WCLC23

2

11

40

Chul Kim

@chulkimMD

8 months

Fascinating keynote by Dr. @christine_lovly . Ground breaking advances in thoracic oncology in the past two decades, exemplified by developments of EGFR targeting therapies. So much work has been accomplished by pioneers and giants in the field (many of whom in the audience).

2

5

41

Chul Kim

@chulkimMD

9 months

Honored to have had medical students from Yonsei University in South Korea rotate at @LombardiCancer for three weeks. We had a farewell lunch today, joined by a special guest who accompanied me in the clinic due to snow day school closure.

2

41

Chul Kim

@chulkimMD

3 years

Of all the data from #CheckMate_816 , the clear separation of the overall survival (OS) curves shortly after year 1 is most impressive to me. We need to see more mature OS data to fully appreciate the impact, but this looks promising. #LCSM

0

6

42

Chul Kim

@chulkimMD

6 years

Our systematic review on checkpoint inhibitor therapy in cancer patients with HIV infection is out! Many thanks to @ConquerCancerFd and Sher research grant from @LombardiCancer for support for this work and other ongoing projects on this topic!

Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer

This systematic review examines the association of immune checkpoint inhibitor therapy with immune-related adverse effects, antitumor activity, and viral load in patients with HIV infection and...

jamanetwork.com

4

21

41

Chul Kim

@chulkimMD

9 months

The most enjoyable aspect of attending a meeting/conference is the opportunity to see #LCSM colleagues and friends! @Latinamd @COlazagasti @DrSteveMartin #WinterLung

2

41

Chul Kim

@chulkimMD

3 years

I feel lucky to have been surrounded by great mentors and colleagues @LombardiCancer . Advancing cancer care is teamwork, and I have the most supportive colleagues one could ask for, including @StephenVLiu and @Joshua_Reuss . I am deeply honored to receive this award.

Stephen V Liu, MD

@StephenVLiu

3 years

Congratulations to Drs. @chulkimMD and @jay_jinani - awardees of this year's John F. Potter, MD Award for rising star researcher at @Georgetown @LombardiCancer ! Thanks for all the work you do!

7

3

36

16

2

40

Chul Kim

@chulkimMD

3 years

It took less than one second to realize that bringing this book was one of my worst decisions in my life

6

1

39

Chul Kim

@chulkimMD

1 year

Hello Chicago. Look forward to exploring latest data and discussing new ideas. Most excited about reconnecting with friends and colleagues, and forging new connections! #ASCO23

2

1

39

Chul Kim

@chulkimMD

1 year

We've just become a part of the cat universe. Introducing ‘Mango’ and ‘Peach’ ⭐️ #CatTwitter #CatsOfTwitter #CatsOnTwitter

6

1

39

Chul Kim

@chulkimMD

3 years

Targeted therapies are not “chemo pills”. That is it. That is the tweet.

1

2

39

Chul Kim

@chulkimMD

1 year

Happiness captured in Jeju Island, South Korea.

1

0

38

Chul Kim

@chulkimMD

2 years

Being able to witness a patient's life milestone, like the anticipated arrival of their first grandchild, is a privilege for an oncologist. This baby shower feels special 🎊

1

0

38

Chul Kim

@chulkimMD

2 years

The bond we build with our patients can be incredibly strong and personal. Sometimes, it leaves a hole in the heart when they are not with us. There are days when the heart feels heavier.

0

2

38

Chul Kim

@chulkimMD

5 years

No new safety signal with treatment with durvalumab in HIV+ patients (n=20, 75% lung cancer) and responses were seen. We should consider broader inclusion of HIV+ patients in clinical trials.

1

19

36

Chul Kim

@chulkimMD

3 years

A single arm phase II trial of carbo/pem/bev/atezo in EGFR-mutant NSCLC after TKI Tx N=40 ORR=62.5% PFS=9.4 mo 1-year OS=72.5% Grade ≥3 TRAE=37.5% (IMpower150=57%) Efficacy similar to IMpower150 regimen with potentially less toxicity @LungCaJournal

2

14

36

Chul Kim

@chulkimMD

4 years

I am one of them. The reason why I decided to move to the U.S. is to become an oncologist who develops better treatments for patients suffering from cancer. The administration's immigration policy has direct negative impacts on many of us, immigrant doctors, caring for patients.

Vincent Rajkumar

@VincentRK

4 years

Many immigrant doctors come to train in the US on J-1 or H-1 visas. They work in various settings from rural underserved areas to academic centers discovering new treatments. If you are an American who sought healthcare, it’s likely you have been cared for by one of us.

15

218

988

1

5

35

Chul Kim

@chulkimMD

2 years

Lucky to be able to catch up with friend/colleague/mentee, Dr. Vince Yeung @RutgersCancer during a quick trip to New Jersey for a meeting. True privilege to see him thrive at his new institution.

0

36

Chul Kim

@chulkimMD

4 years

Follow-up report on pembrolizumab in thymic carcinoma finally out in @JTOonline . With median f/u of 4.9 yrs, ORR remained at 22.5%. Durable responses seen: mDOR 2.99 yrs, mOS 2.12 yrs. Close monitoring on Tx needed given irAEs. Work with #BeppeGiaccone .

2

6

36

Chul Kim

@chulkimMD

2 years

Finally found out why roses 🌹 were not blooming this year..

2

0

36

Chul Kim

@chulkimMD

1 year

Excited to present our research showing high Trop-2 expression in thymic epithelial tumors @LungCaJournal Great work by Dr. Vincent Yeung, former fellow @LombardiCancer A multicenter IIT of sacituzumab govitecan in TETs under design by @jennifermarksmd !

0

9

36

Chul Kim

@chulkimMD

1 year

Insightful talk by Dr. PC Yang. Estimated lung cancer not associated with smoking is up to 30-40% globally. Ongoing efforts to understand the role of lung cancer screening in people without smoking history are underway. Very important topic #ASCO23

0

14

34

Chul Kim

@chulkimMD

4 years

End-of-year thoracic oncology party started!! Wine and food delivered to home. Fantastic idea organized by our fearless leader @StephenVLiu Lucky to work with all the wonderful colleagues @LombardiCancer @MedStarGUH .

1

34

Chul Kim

@chulkimMD

3 years

It was a tough week with loss of two young patients due to rare thoracic tumors. Rare tumors get less resources and attention, leading to less discovery and therapeutic development. How do we challenge the status quo?

4

1

33

Chul Kim

@chulkimMD

1 year

HER2 is a relevant target in many tumor types In DESTINY-PanTumor02, T-DXd showed activity across HER2 expressing many solid tumors ORR 37.1% in all patients and 61.3% in patients with IHC 3+ with DOR 11.8 months in all patients and 22.1 months in patients with IHC 3+! #ASCO23

1

17

34